Staar Surgical Stock Discussion

$Staar Surgical (STAA.US)$ llap up 10%

Upgrades
• $Afya Ltd (AFYA.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $18)
• $Appfolio (APPF.US)$: KeyBanc Upgrades to Overweight from Sector Weight - PT $143
• $C.H. Robinson Worldwide (CHRW.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $117 (from $91)
• $Coupang (CPNG.US)$: Goldman Sachs Upgrades to Conviction Buy from Buy - PT $37
• $Gatos Silver (GATO.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $4
• $ITT Inc (ITT.US)$: UBS Upgr...

Gainers
• $Plantronics (POLY.US)$ +50% (to be acquired by HP Inc ( $HP Inc (HPQ.US)$) for $40.00 per share)
• $Axsome Therapeutics (AXSM.US)$ +21.6% (Jazz Pharma divests Sunosi to Axsome Therapeutics)
• $Staar Surgical (STAA.US)$ +15.4% (receives FDA approval of EVO Visian Implantable Collamer Lenses)
• $Palladyne AI (STRC.US)$ +7.6% (announces that the Company has reached a definitive merger agreement to acquire Pittsburgh-base...

$Staar Surgical (STAA.US)$
Many across the world have already gotten ICL implanted into their eyes to correct their Myopia.
“Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again.
FDA approval brings in the US market, with many prospective users, profits will only go up from here 👍🏻

Upgrades
• $Allstate (ALL.US)$: Raymond James Upgrades to Strong Buy from Outperform - PT $165 (from $145)
• $DigitalBridge Group (DBRG.US)$: JPMorgan Upgrades to Neutral from Underweight - PT $7
• $Garmin (GRMN.US)$: BofA Securities Upgrades to Buy from Neutral - PT $140 (from $165)
• $Guidewire Software (GWRE.US)$: JMP Securities Upgrades to Market Outperform from Market Perform - PT $110
• $MongoDB (MDB.US)$: UBS Upgrades to Buy from Neutral - PT $450 (from $345)...